NICE to partially review Iluvien reimbursement guidance

Iluvien will receive a partial review of reimbursement guidance from the United Kingdom National Institute for Health and Care Excellence, Alimera Sciences announced in a press release.

Current reimbursement for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) is only available for British and Welsh patients who have had their natural lens replaced with an artificial lens. The company said it would be a “significant improvement in reimbursement guidance” if the pseudophakic-only lens restriction was lifted and all patients with diabetic macular edema could be treated.

“We welcome the decision to review the most up-to-date evidence for Iluvien. The current NICE guidance restricting reimbursement to pseudophakic eyes has the unintended consequence of limiting the treatment options available to U.K. patients with a natural lens,” Alimera CEO Dan Myers said in the release. “We believe expanded reimbursement of Iluvien would help many patients and aid the NHS in managing its resources more effectively.”

The partial assessment is expected to be completed next year.

Iluvien will receive a partial review of reimbursement guidance from the United Kingdom National Institute for Health and Care Excellence, Alimera Sciences announced in a press release.

Current reimbursement for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) is only available for British and Welsh patients who have had their natural lens replaced with an artificial lens. The company said it would be a “significant improvement in reimbursement guidance” if the pseudophakic-only lens restriction was lifted and all patients with diabetic macular edema could be treated.

“We welcome the decision to review the most up-to-date evidence for Iluvien. The current NICE guidance restricting reimbursement to pseudophakic eyes has the unintended consequence of limiting the treatment options available to U.K. patients with a natural lens,” Alimera CEO Dan Myers said in the release. “We believe expanded reimbursement of Iluvien would help many patients and aid the NHS in managing its resources more effectively.”

The partial assessment is expected to be completed next year.